Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2015

01-07-2015 | Research Article

The clinical value of dynamic contrast-enhanced MRI in differential diagnosis of malignant and benign ovarian lesions

Authors: Xian Li, Jun-Li Hu, Lai-Min Zhu, Xin-Hai Sun, Hua-Qiang Sheng, Ning Zhai, Xi-Bin Hu, Chu-Ran Sun, Bin Zhao

Published in: Tumor Biology | Issue 7/2015

Login to get access

Abstract

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is widely used in preoperative diagnosis of various tumors. We investigated the clinical value of DCE-MRI in differential diagnosis of malignant and benign ovarian lesions. The study involved 48 subjects with surgical pathology-confirmed ovarian tumors with solid components. Early dynamic phase enhancement performances of the ovarian lesions in patients were assessed, including the enhancement pattern, time-signal intensity curve (TIC), signal intensity rate at the initial 60 s (SI60), time to peak within 200 s (TTP200), and slope ratio. There were significant differences in enhancement patterns between benign and malignant ovarian tumors (P < 0.05). A total of 30 malignant tumors (30/31) displayed type I TIC, 8 benign tumors (8/13) showed type III TIC, and significant differences were found in TIC type between malignant and benign ovarian lesions (P < 0.01). Benign ovarian tumors showed lower SI60 (%) and slope ratio, as well as significantly prolonged TTP20, compared to malignant ovarian tumors (all P < 0.01). The microvessel count (MVC) of malignant tumors was significantly higher than that of benign tumors (P < 0.05). Receiver operating characteristic (ROC) curve analyses revealed that DCE-MRI provided an optimal diagnostic performance with threshold values of SI60 at 83.40 %, TTP200 at 77.65 s, and slope ratio at 4.12. These findings revealed that DCE-MRI provides critical information required for differential diagnosis of malignant and benign ovarian lesions.
Literature
1.
2.
Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol. 2013;129(1):258–64.CrossRefPubMed
3.
Lowe KA, Chia VM, Taylor A, O’Malley C, Kelsh M, Mohamed M, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013;130(1):107–14.CrossRefPubMed
4.
Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin MC, You SL, et al. Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol. 2013;24(4):342–51.CrossRefPubMedPubMedCentral
5.
Wong KH, Mang OW, Au KH, Law SC. Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study. Hong Kong Med J. 2012;18(6):466–74.PubMed
6.
Lutz AM, Willmann JK, Drescher CW, Ray P, Cochran FV, Urban N, et al. Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology. 2011;259(2):329–45.CrossRefPubMed
7.
Gentry-Maharaj A, Menon U. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):243–56.CrossRefPubMed
8.
Cesario S. Advances in the early detection of ovarian cancer: how to hear the whispers early. Nurs Womens Health. 2010;14(3):222–34.CrossRefPubMed
9.
Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of ultrasonography with color Doppler in ovarian tumor: a systematic quantitative review. Int J Gynecol Cancer. 2009;19(7):1214–20.CrossRefPubMed
10.
Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol. 2010;116(3):389–94.CrossRefPubMed
11.
Yuan Y, Gu ZX, Tao XF, Liu SY. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. Eur J Radiol. 2012;81(5):1002–6.CrossRefPubMed
12.
Medeiros LR, Freitas LB, Rosa DD, Silva FR, Silva LS, Birtencourt LT, et al. Accuracy of magnetic resonance imaging in ovarian tumor: a systematic quantitative review. Am J Obstet Gynecol. 2011;204(1):67–e1-10.CrossRefPubMed
13.
Bazot M, Darai E, Nassar-Slaba J, Lafont C, Thomassin-Naggara I. Value of magnetic resonance imaging for the diagnosis of ovarian tumors: a review. J Comput Assist Tomogr. 2008;32(5):712–23.CrossRefPubMed
14.
Sala E, Rockall A, Rangarajan D, Kubik-Huch RA. The role of dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging in the female pelvis. Eur J Radiol. 2010;76(3):367–85.CrossRefPubMed
15.
Heye T, Davenport MS, Horvath JJ, Feuerlein S, Breault SR, Bashir MR, et al. Reproducibility of dynamic contrast-enhanced MR imaging. Part I. Perfusion characteristics in the female pelvis by using multiple computer-aided diagnosis perfusion analysis solutions. Radiology. 2013;266(3):801–11.CrossRefPubMed
16.
Yankeelov TE, Gore JC. Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. Curr Med Imaging Rev. 2009;3(2):91–107.CrossRefPubMedPubMedCentral
17.
Cuenod CA, Balvay D. Perfusion and vascular permeability: basic concepts and measurement in DCE-CT and DCE-MRI. Diagn Interv Imaging. 2013;94(12):1187–204.CrossRefPubMed
18.
Tofts PS. T1-weighted DCE imaging concepts: modelling, acquisition and analysis. Signal. 2010;500(450):400.
19.
Kyriazi S, Kaye SB, deSouza NM. Imaging ovarian cancer and peritoneal metastases—current and emerging techniques. Nat Rev Clin Oncol. 2010;7(7):381–93.CrossRefPubMed
20.
Chen W, Giger ML, Bick U, Newstead GM. Automatic identification and classification of characteristic kinetic curves of breast lesions on DCE-MRI. Med Phys. 2006;33(8):2878–87.CrossRefPubMed
21.
Do RK, Rusinek H, Taouli B. Dynamic contrast-enhanced MR imaging of the liver: current status and future directions. Magn Reson Imaging Clin N Am. 2009;17(2):339–49.CrossRefPubMed
22.
Moon M, Cornfeld D, Weinreb J. Dynamic contrast-enhanced breast MR imaging. Magn Reson Imaging Clin N Am. 2009;17(2):351–62.CrossRefPubMed
23.
Thomassin-Naggara I, Cuenod CA, Darai E, Marsault C, Bazot M. Dynamic contrast-enhanced MR imaging of ovarian neoplasms: current status and future perspectives. Magn Reson Imaging Clin N Am. 2008;16(4):661–72. ix.CrossRefPubMed
24.
Thomassin-Naggara I, Darai E, Nassar-Slaba J, Cortez A, Marsault C, Bazot M. Value of dynamic enhanced magnetic resonance imaging for distinguishing between ovarian fibroma and subserous uterine leiomyoma. J Comput Assist Tomogr. 2007;31(2):236–42.CrossRefPubMed
25.
Pannu HK, Ma W, Zabor EC, Moskowitz CS, Barakat RR, Hricak H. Enhancement of ovarian malignancy on clinical contrast enhanced MRI studies. ISRN Obstet Gynecol. 2013;2013:979345.CrossRefPubMedPubMedCentral
26.
Glas J, Seiderer J, Bues S, Stallhofer J, Fries C, Olszak T, et al. IRGM variants and susceptibility to inflammatory bowel disease in the German population. PLoS One. 2013;8(1):e54338.CrossRefPubMedPubMedCentral
27.
Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, et al. Changes in tumor blood flow as measured by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a gynecologic oncology group phase II study. Gynecol Oncol. 2012;126(3):375–80.CrossRefPubMed
28.
Priest AN, Gill AB, Kataoka M, McLean MA, Joubert I, Graves MJ, et al. Dynamic contrast-enhanced MRI in ovarian cancer: initial experience at 3 tesla in primary and metastatic disease. Magn Reson Med. 2010;63(4):1044–9.CrossRefPubMed
29.
Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123(8):3190–200.CrossRefPubMedPubMedCentral
30.
Yang J, Kim JH, Im GH, Heo H, Yoon S, Lee J, et al. Evaluation of antiangiogenic effects of a new synthetic candidate drug KR-31831 on xenografted ovarian carcinoma using dynamic contrast enhanced MRI. Korean J Radiol. 2011;12(5):602–10.CrossRefPubMedPubMedCentral
31.
Dilks P, Narayanan P, Reznek R, Sahdev A, Rockall A. Can quantitative dynamic contrast-enhanced MRI independently characterize an ovarian mass? Radiology. 2008;20(9):2176–83. 32.
32.
Thomassin-Naggara I, Bazot M, Darai E, Callard P, Thomassin J, Cuenod CA. Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology. 2008;248(1):148–59.CrossRefPubMed
33.
Bernardin L, Dilks P, Liyanage S, Miquel ME, Sahdev A, Rockall A. Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation. Eur Radiol. 2012;22(4):880–90.CrossRefPubMed
34.
Thomassin-Naggara I, Darai E, Cuenod CA, Rouzier R, Callard P, Bazot M. Dynamic contrast-enhanced magnetic resonance imaging: a useful tool for characterizing ovarian epithelial tumors. J Magn Reson Imaging. 2008;28(1):111–20.CrossRefPubMed
35.
Inan N, Arslan A, Akansel G, Anik Y, Balci NC, Demirci A. Dynamic contrast enhanced MRI in the differential diagnosis of adrenal adenomas and malignant adrenal masses. Eur J Radiol. 2008;65(1):154–62.CrossRefPubMed
36.
Fukunaga T, Fujii S, Inoue C, Kato A, Chikumi J, Kaminou T, et al. Accuracy of semiquantitative dynamic contrast-enhanced mri for differentiating type II from type I endometrial carcinoma. J Magn Reson Imaging 2014. doi:10.​1002/​jmri.​24730
37.
Chang YC, Huang YH, Huang CS, Chang PK, Chen JH, Chang RF. Classification of breast mass lesions using model-based analysis of the characteristic kinetic curve derived from fuzzy c-means clustering. Magn Reson Imaging. 2012;30(3):312–22.CrossRefPubMed
38.
Onxley JD, Yoo DS, Muradyan N, MacFall JR, Brizel DM, Craciunescu OI. Comprehensive population-averaged arterial input function for dynamic contrast-enhanced vmagnetic resonance imaging of head and neck cancer. Int J Radiat Oncol Biol Phys. 2014;89(3):658–65.CrossRefPubMed
39.
Hansford BG, Karademir I, Peng Y, Jiang Y, Karczmar G, Thomas S, et al. Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate. Acad Radiol. 2014;21(5):569–77.CrossRefPubMed
40.
Park MY, Jee WH, Kim SK, Lee SY, Jung JY. Preliminary experience using dynamic MRI at 3.0 Tesla for evaluation of soft tissue tumors. Korean J Radiol. 2013;14(1):102–9.CrossRefPubMed
41.
Poncelet E, Delpierre C, Kerdraon O, Lucot JP, Collinet P, Bazot M. Value of dynamic contrast-enhanced MRI for tissue characterization of ovarian teratomas: correlation with histopathology. Clin Radiol. 2013;68(9):909–16.CrossRefPubMed
42.
Hak S, Cebulla J, Huuse EM, Davies Cde L, Mulder WJ, Larsson HB, et al. Periodicity in tumor vasculature targeting kinetics of ligand-functionalized nanoparticles studied by dynamic contrast enhanced magnetic resonance imaging and intravital microscopy. Angiogenesis. 2014;17(1):93–107.CrossRefPubMed
43.
Padhani AR, Dzik-Jurasz A. Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging. 2004;15(1):41–57.CrossRefPubMed
44.
Cuenod CA, Fournier L, Balvay D, Guinebretiere JM. Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdom Imaging. 2006;31(2):188–93.CrossRefPubMed
45.
Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging. 2005;30(3):324–41.CrossRefPubMed
46.
Tang HS, Feng YJ, Yao LQ. Angiogenesis, vasculogenesis, and vasculogenic mimicry in ovarian cancer. Int J Gynecol Cancer. 2009;19(4):605–10.CrossRefPubMed
47.
Pickles MD, Manton DJ, Lowry M, Turnbull LW. Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy. Eur J Radiol. 2009;71(3):498–505.CrossRefPubMed
48.
Jackson A, O’Connor JP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res. 2007;13(12):3449–59.CrossRefPubMed
49.
Yang X, Knopp MV. Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol. 2011;2011:732848.PubMedPubMedCentral
50.
Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, et al. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol. 2012;22(7):1451–64.CrossRefPubMed
Metadata
Title
The clinical value of dynamic contrast-enhanced MRI in differential diagnosis of malignant and benign ovarian lesions
Authors
Xian Li
Jun-Li Hu
Lai-Min Zhu
Xin-Hai Sun
Hua-Qiang Sheng
Ning Zhai
Xi-Bin Hu
Chu-Ran Sun
Bin Zhao
Publication date
01-07-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3219-3

Other articles of this Issue 7/2015

Tumor Biology 7/2015 Go to the issue

Research Article

MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma

Research Article

SUZ12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and E-cadherin

Research Article

miR-155 contributes to the progression of glioma by enhancing Wnt/β-catenin pathway

Research Article

HAS3 underexpression as an indicator of poor prognosis in patients with urothelial carcinoma of the upper urinary tract and urinary bladder

Research Article

Loss of angiotensin-converting enzyme 2 promotes growth of gallbladder cancer

Research Article

Apoptosis of human non-small-cell lung cancer A549 cells triggered by evodiamine through MTDH-dependent signaling pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits